Oramicin

Oramicin sells peptide-based skin-repair topicals and oral nutraceuticals aimed at scar reduction, post-procedure recovery and chronic wound care. Single-unit serums run $89–120 and 30-day supplement packs $110–135, placing the line in the premium tier. Everything is shipped direct from the Irvine, CA headquarters; no retail distribution or Amazon storefront is used. The brand’s distinction is its patented OraPep™ signal-peptide blend, developed from published dermal-regeneration research and manufactured under cGMP pharmaceutical standards. Their hero SKU, RePair-17 Serum, is packaged in nitrogen-flushed, single-dose ampoules and is frequently cited by cosmetic dermatologists for accelerating healing after laser resurfacing. All formulas are steroid-free, fragrance-free and backed by small-batch third-party efficacy data. Core buyers are 30-55-year-old aesthetic patients, athletes recovering from abrasions, and diabetics prone to slow-healing ulcers who value evidence over clean-beauty marketing. They are willing to pay clinic-level prices for medical-grade actives that shorten downtime and minimize scarring without antibiotics or steroids. Oramicin competes against mass scar gels, prescription silicone sheets and high-end post-procedure balms. It differentiates by positioning itself as a clinically dosed peptide therapeutics company rather than a cosmetic skincare line, supplying sealed, dated ampoules that meet pharmacopeial purity specs and offering telehealth-supported usage protocols.